Myocardial Injury Biomarkers and Cardiac Complications Associated with Mortality in Patients with COVID-19
- PMID: 32876196
- PMCID: PMC8384270
- DOI: 10.36660/abc.20200372
Myocardial Injury Biomarkers and Cardiac Complications Associated with Mortality in Patients with COVID-19
Abstract
Background: SARS-CoV-2 is an emerging RNA virus associated with a severe acute respiratory disease known as COVID-19. Although COVID-19 is predominantly a pulmonary disease, some patients have severe cardiovascular damage. We performed a quantitative evidence synthesis of clinical data, myocardial injury biomarkers, and cardiac complications associated with in-hospital death in patients with COVID-19.
Methods: We searched the databases PubMed, Embase, and Google Scholar to identify studies comparing clinical data, myocardial injury biomarkers, and cardiac complications between non-survivors and survivors of COVID-19. Effect sizes were reported as mean difference or standardized mean difference for continuous variables and risk ratio for dichotomous variables with 95% confidence intervals. A random effects model was used to pool the results.
Results: Six retrospective studies reporting data from 1,141 patients (832 survivors and 309 non-survivors) were included. We found that underlying cardiovascular conditions; elevation of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and creatine kinase-MB; and cardiac complications were associated with increased risk of death for patients with SARS-CoV-2 infection.
Conclusions: The confirmation that underlying cardiovascular conditions, elevation of myocardial injury biomarkers during COVID-19 infection, and acute cardiovascular decompensation are predictors for mortality in SARS-CoV-2 infection must encourage new research to clarify potential mechanisms and test appropriate treatments. (Arq Bras Cardiol. 2020; 115(2):273-277).
Fundamento: O SARS-CoV-2 é um vírus de RNA emergente associado à doença respiratória aguda grave conhecida como COVID-19. Embora a COVID-19 seja predominantemente uma doença pulmonar, alguns pacientes apresentam graves danos cardiovasculares. Realizamos uma síntese de evidências quantitativas de dados clínicos, biomarcadores de lesão miocárdica e complicações cardíacas associadas ao óbito hospitalar em pacientes com COVID-19.
Métodos: Buscamos nas bases de dados PubMed, Embase e Google Scholar para identificar estudos que comparassem dados clínicos, biomarcadores de lesão miocárdica e complicações cardíacas entre pacientes sobreviventes e não sobreviventes da COVID-19. Os tamanhos dos efeitos foram apresentados como diferença média ou diferença média padronizada para variáveis contínuas e razão de risco para variáveis dicotômicas, com intervalos de confiança de 95%. Foi utilizado um modelo de efeitos aleatórios para agrupar os resultados.
Resultados: Foram incluídos seis estudos retrospectivos que relataram dados de 1.141 pacientes (832 sobreviventes e 309 não sobreviventes). Verificamos que condições cardiovasculares subjacentes; elevação de troponina cardíaca I de alta sensibilidade; N-terminal do pró-hormônio do peptídeo natriurético do tipo B e creatina quinase-MB; e complicações cardíacas foram associadas ao aumento do risco de óbito em pacientes com infecção por SARS-CoV-2.
Conclusões: A confirmação de que condições cardiovasculares subjacentes, elevação de biomarcadores de lesão miocárdica durante a infecção por COVID-19 e descompensação cardiovascular aguda são preditores de mortalidade na infecção por SARS-CoV-2 deve incentivar novas pesquisas para esclarecer possíveis mecanismos e testar tratamentos adequados. (Arq Bras Cardiol. 2020; 115(2):273-277).
Conflict of interest statement
Potencial conflito de interesses
Os autores declaram não haver conflito de interesses pertinentes.
Similar articles
-
Cardiac Troponin as a Predictor of Myocardial Injury and Mortality from COVID-19.Arq Bras Cardiol. 2020 Oct;115(4):667-668. doi: 10.36660/abc.20200862. Arq Bras Cardiol. 2020. PMID: 33111867 Free PMC article. English, Portuguese. No abstract available.
-
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017. JAMA Cardiol. 2020. PMID: 32219356 Free PMC article.
-
Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19.Diabetes Metab Syndr. 2020 Sep-Oct;14(5):929-931. doi: 10.1016/j.dsx.2020.06.027. Epub 2020 Jun 18. Diabetes Metab Syndr. 2020. PMID: 32590335 Free PMC article. Review.
-
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.Eur Heart J. 2020 Jun 7;41(22):2070-2079. doi: 10.1093/eurheartj/ehaa408. Eur Heart J. 2020. PMID: 32391877 Free PMC article.
-
Potential Effects of Coronaviruses on the Cardiovascular System: A Review.JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286. JAMA Cardiol. 2020. PMID: 32219363 Review.
Cited by
-
Cardiac Manifestations in Patients with COVID-19: A Scoping Review.Glob Heart. 2022 Jan 12;17(1):2. doi: 10.5334/gh.1037. eCollection 2022. Glob Heart. 2022. PMID: 35174043 Free PMC article.
-
Biomarkers Associated with Cardiovascular Disease in COVID-19.Cells. 2022 Mar 8;11(6):922. doi: 10.3390/cells11060922. Cells. 2022. PMID: 35326373 Free PMC article. Review.
-
The Role of Biomarkers in Hospitalized COVID-19 Patients With Systemic Manifestations.Biomark Insights. 2022 Jun 26;17:11772719221108909. doi: 10.1177/11772719221108909. eCollection 2022. Biomark Insights. 2022. PMID: 35783222 Free PMC article. Review.
References
-
- 3. Bauchner H, Golub RM, Zylke J. Editorial concern-possible reporting of the same patients with COVID-19 in different reports. JAMA. 2020;323(13):1256. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous